Kraig Biocraft Laboratories Scales Spider Silk Production with New Facility and Enhanced R&D Capacity
Key Insights
Kraig Biocraft Laboratories (search) has tripled its screening throughput and expanded laboratory capabilities to keep pace with rapid progress in its Project Atlas (search) spider silk (search) program.
The company successfully commissioned a new production rearing center in less than 30 days, which is already operational and supporting record-setting production cycles.
The multi-facility production strategy creates operational redundancy while the standardized approach allows for rapid deployment of additional production capacity throughout 2026.
Kraig Biocraft Laboratories (search) has significantly expanded both its research and development capabilities and production capacity as the biotechnology company accelerates its spider silk (search) commercialization efforts. The company announced a roughly three-fold increase in screening throughput alongside the successful commissioning of a new production facility that came online in less than 30 days.
Enhanced R&D Infrastructure Supports Project Atlas Breakthroughs
The company implemented major laboratory upgrades in direct response to rapid technical progress under Project Atlas (search), its next-generation recombinant spider silk (search) program focused on creating advanced biomaterials with potential industrial and defense applications. The enhanced capabilities include new scientific personnel, advanced equipment deployment, and streamlined screening processes for newly created transgenic lines (search).
"With the pace of discovery we are seeing in Project Atlas (search), it became clear that we needed to expand our screening and analysis capacity to keep up with the speed of innovation," said Kim Thompson, Founder and CEO of Kraig Labs. "This investment in staff and technology further strengthens our position as a leader in advanced biomaterials."
The recently commissioned equipment automates portions of the testing workflow, allowing the research team to rapidly process and evaluate significantly more samples while quickly identifying promising transgenics. Project Atlas (search) is now generating transgenic candidates and potential production materials at the highest levels in the company's history.
Advanced Analytical Capabilities Drive Transgenic Optimization
Kraig Labs has strengthened its analytical testing capabilities to provide deeper insight into expression levels and functional impact of each engineered transgenic line. This enhanced visibility allows researchers to identify the most promising genetic designs and prioritize them for advancement into the production pipeline.
Dr. Zhang, the company's Chief Scientist, emphasized the impact of these upgrades on the research pipeline. "Project Atlas (search) involves the creation and evaluation of numerous complex genetic constructs designed to work together to produce highly specialized silk proteins," said Dr. Zhang. "The expansion of our testing infrastructure dramatically increases our testing capacity to match the increased pace of transgenic creation."
The enhanced screening power enables parallel analysis of multiple transgenic lines (search) while better quantifying how each genetic insert performs. This capability is essential for isolating the highest-performing lines and rapidly advancing them into production.
Rapid Production Scale-Up Through Standardized Facilities
The company's production expansion strategy centers on standardized facility layouts, production workflows, staffing procedures, and operational systems. This approach allows Kraig Labs to quickly duplicate recombinant spider silk (search) production capacity across multiple locations.
The newly commissioned facility is already supporting the company's April/May production cycle, which management expects to set new records as Kraig Labs advances toward commercial-scale recombinant spider silk (search) production. The rapid deployment reflects the company's growing expertise in scaling production operations.
"This new rearing center is already expanding our production," said Thompson. "As we rapidly expand production, we are also increasing efficiency. Each new facility benefits from the experience gained from the previous production runs."
Multi-Facility Strategy Enhances Operational Resilience
The multi-facility production strategy is designed to increase both capacity and resiliency by creating operational redundancy and reducing concentration risk. The approach provides greater flexibility as the company rapidly scales toward commercial production targets.
"We are no longer building one-off pilot operations to test system performance," continued Thompson. "We now have a system that has demonstrated the ability to produce recombinant spider silk (search) at larger and larger scales. This new facility will play a central role in our production as we rapidly move to full commercial scale."
The commissioning follows a series of recent production milestones as part of an aggressive scale-up initiative launched earlier this year. Since then, Kraig Labs has expanded production capacity, deployed new production hybrids, increased cocoon processing throughput, and achieved consecutive record-setting production runs.
Industry Recognition and Future Expansion
The company's leadership in bioengineering was recently featured on the cover of the March 2026 issue of National Geographic, highlighting the growing importance of its work in scaling spider silk (search) production. Management expects to continue deploying additional production capacity throughout 2026 as part of its commercialization roadmap.
By significantly increasing both screening capacity and analytical insight, Kraig Labs expects to shorten development timelines and improve its ability to identify breakthrough material candidates for the global textile industry.